30000 IU Per Week Vitamin D Treatment in PCOS Patients

Vitamin D Deficiency Clinical Trial

Official title:

A Multicentre, Phase-II, Randomised, Double Blind, Placebo-controlled Study to Assess the Safety and the Efficacy of a Weekly Administered Dose of 30,000 IU Vitamin D (Colecalciferol) in Deficient Patients Diagnosed With PCOS

Clinical Trial Details — Status: Suspended

Administrative data

• NCT number: NCT04840238
• Other study ID #: PAT15-PCODD
• Status: Suspended
• Phase: Phase 2
• Start date: December 8, 2016
• Est. completion date: September 2023

Study information

• Verified date: November 2022
• Source: Semmelweis University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a human, II/b phase, multicentre, randomised, double blind, placebo-controlled study to assess the safety and the efficacy of a weekly administered dose of 30,000 IU vitamin D (colecalciferol) in deficient patients diagnosed with PCOS. Investigational products: 30.000 IU vitamin D or placebo administered once a week for 12-weeks-long period, followed by a 12-week-long open label treatment 30.000 IU vitamin D in a follow-up period. Each participant should be checked for regular dietary Ca intake and to assure the optimal calcium level the supplementation is provided with a commercially available Citrocalcium 200 mg tablets. Setting: I. Baseline and screening period: Baseline period considered as when the exogenous Vitamin D intake should not exceed the level of 1000 IU intake per day or a total 5000 NE per week dosages applied (in forms of any Vitamin D3 medication or multivitamin products) at least for 30 days prior the assessment made. II. Double-blind treatment period: Once a week per os applied Vitamin D or placebo treatment for 12 weeks according to randomisation of trial subjects in a 1:1 assignment. By the end of this period an interim assessment will be performed based on the analysis of primary efficacy parameters, stratification to responder and non-responder groups. III. Open label and follow-up phase: An open-label 30000 IU of Vitamin D treatment on weekly basis. (Vitamin D3 Pharma Patent 30000 IU tablets) for additional 12 weeks and continue with the follow-up assessments. A compassionate use of patient diary for additional 26 weeks. Objectives: Primary objectives: to assess the efficacy as a recovery of ovarian function based on progesterone levels and menses diary in at least 20% of trial subjects, compared to placebo treated group Secondary Objectives: assess the efficacy and safety of orally administered vitamin D treatment by the changes in 25(OH) D levels in PCOS patients. Explore the changes in Ovarian-morphology based on the results of standard TVUS Imaging: detection of adverse drug reactions during treatment periods, by frequency and distribution compared to follow-up periods and placebo group. Anticipated participants: 168

Recruitment information / eligibility

• Status: Suspended
• Enrollment: 168
• Est. completion date: September 2023
• Est. primary completion date: February 2022
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Female subject age >18 years.
• Clinical and/or biochemical hyperandrogenism and the proven PCOS by the "Rotterdam" criteria, (ovarian dysfunction, oligo- and/or anovulation, and the morphology of polycystic ovaries on ultrasound images when other etiologies are excluded)
• 25(OH)D levels are between 10-28 ng/ml by inclusion
• Subject can not be under any kind of ongoing hormone or metformin therapies and no indication that requires continuation
• Has the ability and willingness to understand and comply with study procedures and to give written informed consent prior to enrollment in the study or initiation of study procedures
• Study subject has the ability and willingness to understand and comply with study procedures and to give written informed consent prior to enrollment in the study or initiation of study procedures

Exclusion Criteria:

• Has been exposed to any investigational agent within 3 month of enrolment to the study
• Sever metabolic disease on endocrine disease in etiology different from PCOS
• Significant obesity (BMI> 36)
• Any other signs of lab results that may lead to other etiologies in differentiation, or menopause
• Increased serum calcium level results or symptoms of hypercalcemia in last one year
• Hypercalciuria or kidney stone appearance in last one year
• Sever kidney diseases (CKD 3 or higher)
• Chronic or serious disease, which can significantly influence the absorption, metabolism of vitamin D or Ca
• Heart failure or angina pectoris,
• More than 1000 IU vitamin D per day intake or in total >5000 IU per week within 1 month prior to trial (in any forms medication, or nutritional food supplement). The patient is not under hormonal therapy for ovulation stimulation purposes and was not involved in two months prior the study
• The patient is under hormonal therapy for the aim of ovulation stimulation or was involved in within 3 months prior the study
• Existence or suspected gravidity
• Any other finding or symptoms which are by the opinion of the Investigator may indicate a potential interference with the safety of participating trial subjects
• Has a known hypersensitivity to any of the investigational drug or vehicle components.
• Concomitant medication which is not allowed:
• glycosides
• metformin
• magnesium-containing preparations (antacids)
• cholestyramine and other ion exchange resins, orlistat
• thiazide diuretics
• regular use of microsomal enzyme inducers (anticonvulsants, sedatives, etc.).
• corticosteroids (except for dermatological use)
• products containing phosphorus
• regular use of laxatives (such as paraffin oil)
• fat absorption inhibitory drugs
• any kind of hormone therapy (including therapeutic use of birth control pills, within 2 months prior inclusion) except treatment of stabile hypothyroidism

Related Conditions & MeSH terms

• Polycystic Ovary Syndrome
• Vitamin D Deficiency

Intervention

Drug:
• Cholecalciferol
30,000IU cholecalciferol
• Placebo
Placebo tablets

Locations

Country	Name	City	State
Hungary	MediMOM Healthy Center	Budapest
Hungary	Róbert Károly Hospital	Budapest
Hungary	Semmelweis University - Departement Medicine and Oncology	Budapest
Hungary	Gynpraxis Nogyógyászat	Debrecen
Hungary	Somogy County Kaposi Mór Teaching Hospital	Kaposvár
Hungary	Borsod-Abaúj-Zemplén County Hospital	Miskolc
Hungary	SZTE-ÁOK - 1st Dept. of Internal MEdicine	Szeged
Hungary	Gynofarm Outpatient Clinic	Székesfehérvár

Sponsors (2)

Lead Sponsor	Collaborator
Semmelweis University	Pharma Patent Kft.

Country where clinical trial is conducted

Hungary, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Recovery of ovarian function	Recovery of ovarian function is detected by changes in progesterone levels (lutal phase progesterone level reaches 2 ng/ml)	Up to 32 weeks, continuously
Secondary	Length of menstrual cycle	Determined by patient reported number of days between two menstrual cycles	Up to 32 weeks
Secondary	Variation in menstrual cycles length	Determined by patient reported menstrual cycle length and regularity, measured in days	Up to 32 weeks
Secondary	Incidence of adverse events	Incidence of adverse events (safety and tolerability), evaluated at every visit	Up to 32 weeks, continuously
Secondary	Change in serum calcium level	Change in serum calcium levels in mmol/l (safety measure), evaluated every clinical visit	Up to 32 weeks, continuously
Secondary	Change in urinary calcium/creatinine ratio	Change in urinary calcium/creatinine ratio ([mmol/l]/[umol/l]) (safety measure), evaluated every clinical visit	Up to 32 weeks
Secondary	25(OH)D levels	Evaluation of treatment of changes in 25(OH)D blood levels compared between treatment groups	Up to 32 weeks
Secondary	Change in fasting glucose level	Change in fasting glucose level (mmol/l), measured at every visit	Up to 32 weeks
Secondary	Change in hemoglobin A1c level	Change in hemoglobin A1c level (IFCC validated, mmol/mol), measured every 12 weeks	Up to 32 weeks
Secondary	Change in ovarian morphology	Changes in ovarian follicle count assessed by TVUS and evaluated by the Rotterdam criteria (having 12 or more follicles, measuring between 2 and 9 mm)	Up to 32 weeks